Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Cureus ; 15(7): e42716, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37654938

ABSTRACT

BACKGROUND: The most common cause of acute urinary retention in men over 50 is benign prostate enlargement (BPE). Following the urethral catheterization, a trial without a catheter (TWOC) under the cover of alpha-blockers is given. The timing of TWOC varies from Day 3 to Day 7 of the retention episode. There is a need to study the improvement in the success rate of TWOC with the increasing number of days of catheterization. OBJECTIVE: To measure the success rate of TWOC in acute urinary retention due to benign prostatic enlargement with increasing days of catheterization. METHOD: The study was conducted in Social Security Teaching Hospital Lahore. Patients who presented with acute urinary retention due to benign prostatic enlargement were catheterized and given alpha-blockers. The patients were divided into two groups, one group having TWOC after three days and the other having TWOC after seven days. The success rate of TWOC was calculated and compared in the two groups. All patients included in the study had the first episode of acute retention with a moderately enlarged prostate and no element of second pathology or neurological deficit. RESULTS: A total of 48 patients were included in the study, divided into two groups of 24 patients each. In the first group who underwent TWOC after seven days of catheterization, 15 out of 24 patients had successful TWOC with a success rate of 62.5%. In the second group of 24 patients, who had TWOC after three days of catheterization, only 11 patients had successful TWOC with a success rate of 45.8%. CONCLUSION: There was a marked improvement in the success rate of TWOC with increasing days of catheterization after an acute retention episode, secondary to BPE.

2.
J Cutan Aesthet Surg ; 12(3): 179-182, 2019.
Article in English | MEDLINE | ID: mdl-31619890

ABSTRACT

Correction of depigmentation of postburn leukodermic scars is daunting. In contrast to vitiligo, the success rate of skin grafting techniques is much lower in postburn scars owing to altered skin architecture and poor graft uptake. Cellular transfer techniques such as noncultured epidermal or epidermal or keratinocyte suspension suffer the limitations of modest efficacy and high procedural cost. Follicular transplantation by the follicular unit extraction technique is being extensively used in vitiligo. Recently, it has been reported for the correction of scar alopecia. Although this approach is expected to significantly repigment pliant scars, the cosmetic unacceptability of the retained hairs may warrant removal. We describe an innovative three-step protocol to provide a repigmented smooth scar. We vernacularly labeled this technique follicular unit "exploitation," as the follicular units "exploited" positively for repigmentation were later removed by laser hair reduction.

3.
Dermatol Ther ; 29(6): 406-412, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27528547

ABSTRACT

Pathogenesis of vitiligo is believed to be multifactorial disease with a wide variety of therapeutic modalities. The aim of this work is to assess the efficacy of oral mini-pulse steroids (OMP) plus Nb-U.V.B in comparison to OMP alone and Nb-U.V.B alone in treating stable vitiligo. A prospective randomized controlled study including 45 patients categorized into three groups receiving therapy for 3 months; Group A received Nb-U.V.B plus OMP, Group B received OMP alone while Group C received Nb-U.V.B alone. Clinical assessment and PCR evaluation of bFGF, ICAM1, and ELISA for AMA were done. Patients receiving Nb-U.V.B plus OMP and using Nb-U.V.B alone gave statistically significant clinical response than those treated with OMP alone. Statistically significant rise of BFGF was noticed after treatment with Nb-U.V.B plus OMP and with Nb-U.V.B alone. Patients treated with OMP alone and with Nb-U.V.B alone showed statistically significant drop of ICAM-1 after therapy. NB-U.V.B plus OMP and Nb-U.V.B alone were found to be clinically superior over OMP alone in treating stable vitiligo patients, hence suggesting that adding OMP to Nb-U.V.B can maintain clinical and laboratory success for a longer period of time and with less relapse.


Subject(s)
Glucocorticoids/administration & dosage , Prednisone/administration & dosage , Skin Pigmentation/drug effects , Skin Pigmentation/radiation effects , Ultraviolet Therapy , Vitiligo/therapy , Administration, Oral , Adolescent , Adult , Aged , Autoantibodies/blood , Combined Modality Therapy , Egypt , Female , Fibroblast Growth Factor 2/genetics , Glucocorticoids/adverse effects , Humans , Intercellular Adhesion Molecule-1/genetics , Male , Middle Aged , Prednisone/adverse effects , Prospective Studies , Pulse Therapy, Drug , Time Factors , Treatment Outcome , Ultraviolet Therapy/adverse effects , Vitiligo/blood , Vitiligo/genetics , Vitiligo/physiopathology , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...